UZ Antwerpen - Department of Oncology
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Raskin, Jo
SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Recruiting
3
700
Europe, Japan, US, RoW
Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo
Eli Lilly and Company, AstraZeneca
Carcinoma, Non-Small-Cell Lung
05/28
12/31
ALKALINE, NCT04127110 / 2019-003862-41: Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

Active, not recruiting
2
68
Europe, RoW
Lorlatinib
European Organisation for Research and Treatment of Cancer - EORTC, European Organisation for the Research and Treatment of Cancer, Pfizer NV/SA, European Organization for the Research and Treatment of Cancer (EORTC)
Non Small Cell Lung Cancer
07/24
11/24
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Active, not recruiting
1/2
61
Europe, Japan, US, RoW
M1774, Tuvusertib, Cemiplimab
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Non-Small Cell Lung Cancer
05/25
02/26
HYDRA, NCT04657120: Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy

Recruiting
N/A
1566
Europe
YEARS algorithm, CTPA
University Hospital, Brest, Leiden University Medical Center, Insel Gruppe AG, University Hospital Bern, University Hospital, Antwerp
Pulmonary Embolism, Embolism, Embolism and Thrombosis, Vascular Diseases, Cardiovascular Diseases, Lung Diseases, Respiratory Tract Diseases, Cancer, Diagnosis
05/24
05/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Raskin, Jo
SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Recruiting
3
700
Europe, Japan, US, RoW
Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo
Eli Lilly and Company, AstraZeneca
Carcinoma, Non-Small-Cell Lung
05/28
12/31
ALKALINE, NCT04127110 / 2019-003862-41: Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

Active, not recruiting
2
68
Europe, RoW
Lorlatinib
European Organisation for Research and Treatment of Cancer - EORTC, European Organisation for the Research and Treatment of Cancer, Pfizer NV/SA, European Organization for the Research and Treatment of Cancer (EORTC)
Non Small Cell Lung Cancer
07/24
11/24
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Active, not recruiting
1/2
61
Europe, Japan, US, RoW
M1774, Tuvusertib, Cemiplimab
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Non-Small Cell Lung Cancer
05/25
02/26
HYDRA, NCT04657120: Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy

Recruiting
N/A
1566
Europe
YEARS algorithm, CTPA
University Hospital, Brest, Leiden University Medical Center, Insel Gruppe AG, University Hospital Bern, University Hospital, Antwerp
Pulmonary Embolism, Embolism, Embolism and Thrombosis, Vascular Diseases, Cardiovascular Diseases, Lung Diseases, Respiratory Tract Diseases, Cancer, Diagnosis
05/24
05/24

Download Options